320 related articles for article (PubMed ID: 11322281)
1. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
2. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
3. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
Rezza G; Galai N; Pezzotti P; Vlahov D; Graham NM; Viale P; Angarano G
Antivir Ther; 1997 Jul; 2(3):167-74. PubMed ID: 11322271
[TBL] [Abstract][Full Text] [Related]
4. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Rubio A; Gómez-Cano M; Puig T; Leal M; Pérez-Olmeda M; Ruiz L; Clotet B; Rey C; Zamora L; Xaus N; Soriano V
Antivir Ther; 1999; 4(1):45-9. PubMed ID: 10682128
[TBL] [Abstract][Full Text] [Related]
5. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
[TBL] [Abstract][Full Text] [Related]
6. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
[TBL] [Abstract][Full Text] [Related]
7. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
[TBL] [Abstract][Full Text] [Related]
8. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
Opravil M; Hill AM; DeMasi R; Dawson D
Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134
[TBL] [Abstract][Full Text] [Related]
9. Quantification of HIV-1 RNA during antiretroviral therapy: association with viral phenotype and development of resistance.
Katzenstein TL; Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
Antivir Ther; 1996 Dec; 1(4):246-54. PubMed ID: 11324827
[TBL] [Abstract][Full Text] [Related]
10. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study.
Leal M; Torres Y; Medrano FJ; Rey C; Caruz A; Sánchez-Quijano A; Lissen E
Eur J Clin Invest; 1996 Oct; 26(10):923-8. PubMed ID: 8911867
[TBL] [Abstract][Full Text] [Related]
13. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
15. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H
AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742
[TBL] [Abstract][Full Text] [Related]
16. Quantitative p24 antigenaemia for monitoring response to antiretroviral therapy in HIV-1 group O-infected patients.
Machuca A; Gutiérrez M; Mur A; Soriano V
Antivir Ther; 1998; 3(3):187-9. PubMed ID: 10682137
[TBL] [Abstract][Full Text] [Related]
17. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
18. T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.
Naugler WE; Yong FH; Carey VJ; Dragavon JA; Coombs RW; Frenkel LM
J Infect Dis; 2002 Feb; 185(4):448-55. PubMed ID: 11865396
[TBL] [Abstract][Full Text] [Related]
19. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y
J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320
[TBL] [Abstract][Full Text] [Related]
20. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
Rusconi S; De Pasquale MP; Milazzo L; Moscatelli G; Bulgheroni E; Citterio P; d'Arminio-Monforte A; Moroni M; Galli M
Antivir Ther; 1997 Jan; 2(1):39-46. PubMed ID: 11322265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
